The new outbreak of the SARS-CoV-2 coronavirus is causing an important pandemic affecting a large number of people all-over the world. Vitamin D is a hormone precursor produced by our own body with the help of sunlight which has an important role on adaptive immunity and cellular differentiation, maturation and proliferation of several immune cells. Reduced levels of vitamin D in calves were positioned as the main cause of bovine coronavirus infection in the past. Therefore, it seems plausible that the use of vitamin D as a nutritional ergogenic aid could be a potential intervention to fight against COVID-19 infected patients which remain asymptomatic or which have non-severe and severe symptoms. This study aims to investigate whether the use of vitamin D as an immune modulator agent induces significant improvements of health status and outcomes in non-severe symptomatic patients infected with COVID-19 as well as preventing COVID-19 health deterioration. We hypothesize that vitamin D will significantly improve hard endpoints related to COVID-19 deleterious consequences compared with a usual care control group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
Universidad de Granada
Granada, Andalusia, Spain
Medicine Faculty
Granada, Spain
Composite of cumulative death (i.e. mortality) for all causes and for specific causes.
Time frame: Through study completion, an average of 10 weeks
Necessity of invasive assisted ventilation
Time frame: Through study completion, an average of 10 weeks
Necessity of non-invasive assisted ventilation
Time frame: Through study completion, an average of 10 weeks
Intensive care unit admission
Time frame: Through study completion, an average of 10 weeks
Post-anesthesia care unit admission
Time frame: Through study completion, an average of 10 weeks
Hospital admission
Time frame: Through study completion, an average of 10 weeks
Medical consultation
Time frame: Through study completion, an average of 10 weeks
Home care and isolation time
Time frame: Through study completion, an average of 10 weeks
Bed rest time
Time frame: Through study completion, an average of 10 weeks
symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)
Time frame: Through study completion, an average of 10 weeks
Subjective perception of recovery
It will be measure by questionnaire
Time frame: Through study completion, an average of 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.